Safe Launch Concept Sample Clauses

Safe Launch Concept. Supplier shall apply a Safe Launch (SLC) concept for the component as defined during the APQP process and agreed by Xxxxxxxxxx. The purpose of the SLC is to document Supplier's control of its processes during start-up and ramp-up phase, it shall also enable the Supplier to quickly identify and quickly correct any quality issues that may arise at Supplier's location. SLC includes special verifications performed by Supplier for a defined timeframe or quantity as determined together with Stoneridge in the APQP process. SLC requires a Pre-Launch Control Plan, which is a significant enhancement to Supplier's production control plan and which in turn will raise the confidence level to ensure that all components shipped initially will meet Xxxxxxxxxx's expectations. The Pre-launch control plan will also serve to validate the production control plan. The Pre-Launch Control Plan shall take into consideration all known critical conditions of the product as determined with Stoneridge as well as potential areas of concerns in Supplier’s process as also identified during the introduction and PPAP. Supplier shall generate the Pre-Launch Control Plan prior to start of series production and shall make it available to Stoneridge for approval prior to start of series production. Stoneridge shall be entitled to require changes. Suppliers are required to submit SLC data to Stoneridge. This should include variable measurement data where applicable. Suppliers may exit the safe launch process if they have achieved SLC targets unless otherwise specified by Stoneridge. Supplier shall develop action plans to address missed failure modes or capability improvement needs. Stoneridge may require suppliers to perform production on stock for product and process verification purpose. Missing achievement of the SLC targets within the mutual defined period of time or quantities may lead to a withdrawal of the release.
Sample 1Sample 2
AutoNDA by SimpleDocs
Safe Launch Concept. The Supplier shall apply a Safe Launch Concept (SLC) according to the product and process maturity. The scale of the SLC shall be defined during the APQP process and agreed by Continental. The purpose of the SLC is to document the Supplier's control of its processes during start-up and ramp-up phase, it shall also enable the Supplier to quickly identify and quickly correct any quality issues that may arise at the Supplier's location. SLC includes special verifications performed by the Supplier for a defined timeframe or quantity as determined together with Continental in the APQP process. SLC requires a Pre-Launch Control Plan, which is a significant enhancement to the Supplier's production control plan and which in turn will raise the confidence level to ensure that all components shipped initially will meet Continental's expectations. The Pre-launch control plan will also serve to validate the production control plan. The Pre-Launch Control Plan shall take into consideration all known critical conditions of the product as determined with Continental as well as potential areas of concerns in the Supplier’s process as also identified during the introduction and PPAP. The Supplier shall generate the Pre-Launch Control Plan prior to start of series production and shall make it available to Continental for approval prior to start of series production. Continental shall be entitled to request changes. Suppliers are required to submit inspection data to Continental's plant. This should include variable measurement data where applicable. Suppliers may exit the safe launch process if they have achieved SLC targets unless otherwise specified by Continental. Suppliers shall develop action plans to address missed failure modes or capability improvement needs. Continental may require suppliers to perform production on stock for product and process verification purpose. Missing achievement of the SLC targets within the mutual defined period of time or quantities may lead to a withdrawal of the release.
Sample 1

Related to Safe Launch Concept

  • System Impact Study An assessment by the Transmission Provider of (i) the adequacy of the Transmission System to accommodate a Completed Application, an Interconnection Request or an Upgrade Request, (ii) whether any additional costs may be incurred in order to provide such transmission service or to accommodate an Interconnection Request, and (iii) with respect to an Interconnection Request, an estimated date that an Interconnection Customer’s Customer Facility can be interconnected with the Transmission System and an estimate of the Interconnection Customer’s cost responsibility for the interconnection; and (iv) with respect to an Upgrade Request, the estimated cost of the requested system upgrades or expansion, or of the cost of the system upgrades or expansion, necessary to provide the requested incremental rights.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act.

  • Product Changes Vocera shall have the right, in its absolute discretion, without liability to End User, to update to provide new functionality or otherwise change the design of any Product or to discontinue the manufacture or sale of any Product. Vocera shall notify End User at least 90 days prior to the delivery of any Product which incorporates a change that adversely affects form, fit or function (“Material Change”). Vocera shall also notify End User at least 90 days prior to the discontinuance of manufacture of any Product. Notification will be made as soon as reasonably practical for changes associated with regulatory or health and safety issues.

  • DRUG/ALCOHOL TESTING 11.1 The parties agree that the maintenance of a drug/alcohol free work place is a goal of both the College and the Union. Employees are prohibited from possession, consumption and/or being under the influence of a controlled substance/alcohol while on the College’s premises or during time paid by the employer. Violations of this prohibition may result in a disciplinary action up to and including termination.

  • Curriculum Vitae (a) The Chief Librarian shall maintain a curriculum vita for each Librarian. It is the Librarian’s responsibility to ensure that the curriculum vita on file is kept current. Members shall prepare their curriculum vita with the advice and assistance of their Chief Librarian. Members may revise their curriculum vita at any time.

  • REGULATORY FILINGS AND CAISO TARIFF COMPLIANCE 3.1 Filing

  • Synchronization, Commissioning and Commercial Operation 4.1.1 The Power Producer shall give at least thirty (30) days written notice to the SLDC and GUVNL, of the date on which it intends to synchronize the Power Project to the Grid System.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Creative Commons Attribution-Non-Commercial-NoDerivs License The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BY-NC-ND) permits use, distribution and reproduction in any medium, provided the original work is properly cited, is not used for commercial purposes and no modifications or adaptations are made. (see below) Use by commercial "for-profit" organizations Use of Wiley Open Access articles for commercial, promotional, or marketing purposes requires further explicit permission from Wiley and will be subject to a fee. Further details can be found on Wiley Online Library xxxx://xxxxxxx.xxxxx.xxx/WileyCDA/Section/id-410895.html Other Terms and Conditions:

  • Power Factor Design Criteria (Reactive Power A wind generating plant shall maintain a power factor within the range of 0.95 leading to 0.95 lagging, measured at the Point of Interconnection as defined in this LGIA, if the ISO’s System Reliability Impact Study shows that such a requirement is necessary to ensure safety or reliability. The power factor range standards can be met using, for example without limitation, power electronics designed to supply this level of reactive capability (taking into account any limitations due to voltage level, real power output, etc.) or fixed and switched capacitors if agreed to by the Connecting Transmission Owner for the Transmission District to which the wind generating plant will be interconnected, or a combination of the two. The Developer shall not disable power factor equipment while the wind plant is in operation. Wind plants shall also be able to provide sufficient dynamic voltage support in lieu of the power system stabilizer and automatic voltage regulation at the generator excitation system if the System Reliability Impact Study shows this to be required for system safety or reliability.

Time is Money Join Law Insider Premium to draft better contracts faster.